Karamali Maryam, Nourgostar Sepideh, Zamani Ashraf, Vahedpoor Zahra, Asemi Zatollah
1Department of Gynecology and Obstetrics,School of Medicine,Arak University of Medical Sciences,PO Box 3819693345,Arak,Iran.
3Department of Gynecology and Obstetrics,School of Medicine,Kashan University of Medical Sciences,PO Box 8715988141,Kashan,Iran.
Br J Nutr. 2015 Dec 28;114(12):2039-45. doi: 10.1017/S0007114515003852. Epub 2015 Oct 6.
This study was conducted to assess the effects of long-term Se administration on the regression and metabolic status of patients with cervical intraepithelial neoplasia grade 1 (CIN1). This randomised, double-blind, placebo-controlled trial was carried out among fifty-eight women diagnosed with CIN1. To diagnose CIN1, we used specific diagnostic procedures of biopsy, pathological diagnosis and colposcopy. Patients were randomly assigned to two groups to receive 200 μg Se supplements as Se yeast (n 28) or placebo (n 28) daily for 6 months. After 6 months of taking Se supplements, a greater percentage of women in the Se group had regressed CIN1 (88·0 v. 56·0 %; P=0·01) compared with those in the placebo group. Long-term Se supplementation, compared with the placebo, resulted in significant decreases in fasting plasma glucose levels (-0·37 (sd 0·32) v. +0·07 (sd 0·63) mmol/l; P=0·002), serum insulin levels (-28·8 (sd 31·2) v. +13·2 (sd 40·2) pmol/l; P<0·001), homeostatic model assessment of insulin resistance values (-1·3 (se 1·3) v. +0·5 (se 1·4); P<0·001) and a significant elevation in quantitative insulin sensitivity check index (+0·03 (sd 0·03) v. -0·01 (sd 0·01); P<0·001). In addition, patients who received Se supplements had significantly decreased serum TAG (-0·14 (sd 0·55) v. +0·15 (sd 0·38) mmol/l; P=0·02) and increased HDL-cholesterol levels (+0·13 (sd 0·21) v. -0·01 (sd 0·15) mmol/l; P=0·003). In addition, compared with the placebo group, there were significant rises in plasma total antioxidant capacity (+186·1 (sd 274·6) v. +42·8 (sd 180·4) mmol/l; P=0·02) and GSH levels (+65·0 (sd 359·8) v. -294·2 (sd 581·8) μmol/l; P=0·007) and a significant decrease in malondialdehyde levels (-1·5 (sd 2·1) v. +0·1 (sd 1·4) μmol/l; P=0·001) among those who took Se supplements. Overall, taking Se supplements among patients with CIN1 led to its regression and had beneficial effects on their metabolic profiles.
本研究旨在评估长期补充硒对宫颈上皮内瘤变1级（CIN1）患者病情消退及代谢状况的影响。这项随机、双盲、安慰剂对照试验在58例被诊断为CIN1的女性中开展。为诊断CIN1，我们采用了活检、病理诊断及阴道镜检查等特定诊断程序。患者被随机分为两组，一组每日服用200μg硒酵母补充剂（n = 28），另一组服用安慰剂（n = 28），为期6个月。服用硒补充剂6个月后，与安慰剂组相比，硒组中病情消退的女性比例更高（88.0%对56.0%；P = 0.01）。与安慰剂相比，长期补充硒可使空腹血糖水平显著降低（-0.37（标准差0.32）对+0.07（标准差0.63）mmol/L；P = 0.002）、血清胰岛素水平显著降低（-28.8（标准差31.2）对+13.2（标准差40.2）pmol/L；P<0.001）、胰岛素抵抗稳态模型评估值显著降低（-1.3（标准误1.3）对+0.5（标准误1.4）；P<0.001），并使定量胰岛素敏感性检查指数显著升高（+0.03（标准差0.03）对-0.01（标准差0.01）；P<0.001）。此外，服用硒补充剂的患者血清甘油三酯显著降低（-0.14（标准差0.55）对+0.15（标准差0.38）mmol/L；P = 0.02），高密度脂蛋白胆固醇水平升高（+0.13（标准差0.21）对-0.01（标准差0.15）mmol/L；P = 0.003）。此外，与安慰剂组相比，服用硒补充剂的患者血浆总抗氧化能力显著升高（+186.1（标准差274.6）对+42.8（标准差180.4）mmol/L；P = 0.02）、谷胱甘肽水平显著升高（+65.0（标准差359.8）对-294.2（标准差581.8）μmol/L；P = 0.007），丙二醛水平显著降低（-1.5（标准差2.1）对+0.1（标准差1.4）μmol/L；P = 0.001）。总体而言，CIN1患者服用硒补充剂可使其病情消退，并对其代谢状况产生有益影响。
